- Beta Blockers for POTS: What the Evidence Actually Says - 10 August 2026
- Duloxetine (Cymbalta) for Fibromyalgia: What the Evidence Actually Says - 10 August 2026
- Gabapentin for Fibromyalgia: What the Evidence Actually Says - 7 August 2026
Beta blockers are the drug most people with POTS get handed first, usually before anyone has explained what they do, why the dose matters, or whether they suit the kind of POTS you actually have. You get a prescription, you take the tablet, and one of three things happens: your heart rate settles and you feel better, nothing much changes, or you end up flatter and more exhausted than you were before. The odd part is that all three of those outcomes can happen with the same drug, and a lot of the difference comes down to how much of it you’re taking. That’s not a small detail. It’s arguably the single most important thing to understand about this class of medication, and it’s the bit that almost nobody explains.
If you’ve been living with postural tachycardia syndrome for a while, you’ll know the feeling of being handed a medication with almost no context. You stand up, your heart races, you feel dizzy and wired and wrung out, and someone suggests a beta blocker to bring the rate down. Reasonable enough on the face of it. The trouble is that POTS is not one thing, beta blockers are not one dose, and the research on them is genuinely more interesting than the leaflet lets on.
So here’s what this article is going to do. We’re going to go through what beta blockers actually do to a POTS body, look at what the real evidence says (not what the leaflet says, not what a rushed appointment implies, but what the trials and the guidelines actually found), and be honest about what works, what doesn’t, and what sits somewhere in the murky middle. We’ll cover the low dose versus high dose puzzle that trips up so many people, why propranolol tends to get picked over the cardioselective options, who beta blockers genuinely suit, who they can make worse, and where they sit alongside the plainer work of salt, fluid, compression and graded exercise that does most of the heavy lifting.
One quick note before we start. This article is not medical advice, and I’m not your prescriber. What it is, is a thorough read of the evidence so you can have a better, more informed conversation with the people who do prescribe for you. Nothing here is a reason to start, stop or change a medication on your own. Right, that’s the housekeeping done. If you’re ready to actually understand the drug that’s probably already in your cupboard, let’s go.
What beta blockers actually do in POTS
Before we get to the medication, we need to understand why the heart rate does what it does in POTS, because this is the bit that gets missed constantly, and it’s the reason beta blockers help some people and flatten others. When you stand up, gravity pulls a good chunk of your blood down into your legs and abdomen. In a body that handles this well, the blood vessels tighten, the return of blood to the heart holds up, and the heart rate rises just a little to keep everything ticking over. In POTS, that compensation goes into overdrive. The heart rate leaps by 30 beats per minute or more within ten minutes of standing (40 or more in teenagers), and it does this without a meaningful drop in blood pressure, which is what separates POTS from a simple faint.[4] The racing heart isn’t the disease. It’s the body’s clumsy attempt to solve a circulation problem, and it usually overshoots.
That overshoot is driven by your sympathetic nervous system, the fight or flight side of things, leaning on the heart through adrenaline and noradrenaline. These chemicals dock onto beta adrenergic receptors, and the beta 1 receptors sitting on the heart’s own pacemaker, the sinoatrial node, are the ones that crank the rate up. A beta blocker does more or less what the name suggests. It sits in front of those receptors so adrenaline and noradrenaline can’t rev the heart as hard, and the standing heart rate comes down.[1] Think of it as taking your foot slightly off an accelerator that’s been stuck too far down. That’s obviously a simplification, but it captures the general idea.
On paper, that sounds like exactly what you’d want. Racing heart, drug that slows the heart, problem solved. In practice it’s more complicated, because slowing the heart is not the same as fixing how you feel, and in some people a slower heart pumping less blood per beat leaves them worse off rather than better. That gap between the number on the monitor and how a person actually feels is where the most useful finding about beta blockers in POTS lives, and it’s the part most articles skip straight past.
The dose paradox: why less can beat more
Here is the finding that should be printed on the box. In POTS, a low dose of propranolol works better than a high dose, even though the high dose slows the heart more. That sounds back to front, so let me show you where it comes from.
The landmark study here was run by Satish Raj and colleagues at Vanderbilt and published in Circulation in 2009.[1] They gave people with POTS a single low dose of propranolol (20 mg) or a placebo, and measured what happened to standing heart rate and symptoms. The low dose brought the standing heart rate down from around 110 to around 90 beats per minute, a clear and statistically solid drop, and it improved people’s overall symptom burden. So far, so predictable. Then they compared that same 20 mg dose against a much bigger 80 mg dose. The 80 mg dose lowered the heart rate even further, down into the high 70s, so if heart rate were the whole story, it should have been the winner. It wasn’t. The symptom improvement was actually better on the low dose than the high one. More blocking, more slowing, less benefit.
A few years later, a separate Vanderbilt team led by Amy Arnold looked at exercise capacity, which matters enormously if you’re trying to rebuild any kind of tolerance to activity.[2] Low dose propranolol improved how much work people with POTS could do, nudging their peak oxygen uptake up and bringing their runaway exercise heart rate under control, and it did this partly by letting the heart fill better and push out a bigger volume with each beat. Interestingly, the same low dose did nothing for the healthy control group, which tells you the benefit is specific to the over-revved POTS physiology, not a general fitness boost. And when they tested the high 80 mg dose, alongside a high dose of a different beta blocker, the exercise benefit vanished. Same pattern as before: low helps, high doesn’t.
So why does more end up being worse? The most sensible explanation is that your heart rate on standing isn’t purely a nuisance, it’s doing a job. Some of that extra rate is compensating for the fact that less blood is coming back to the heart. Blunt it a little and you take the edge off the pointless overshoot. Blunt it too hard and you cut into the compensation the body genuinely needs, so cardiac output falls, less blood reaches the brain and muscles, and you’re left more tired, more foggy and less able to move than before. The Canadian Cardiovascular Society puts this almost as plainly in its 2020 position statement, which is one of the clearest documents on POTS treatment going. Higher doses and long acting formulations might lower standing heart rate, but they’re generally ineffective at controlling symptoms, they’re not recommended, and their side effects can include worse exercise tolerance and worse fatigue.[4] Sometimes more isn’t more, it’s just more side effects.
There’s a practical lesson buried in here, and it’s one worth taking to an appointment. If you were started on a beta blocker, felt flattened by it, and concluded that beta blockers just aren’t for you, it’s genuinely possible the dose was simply too high for your physiology rather than the drug being wrong. That same guideline recommends a starting range at the low end, in the region of 10 to 20 mg of propranolol taken a few times a day, precisely because the aim is to shave the top off the tachycardia, not to sedate the heart.[4] The temptation, for both the person taking it and the prescriber, is to assume that if a little helps then more will help more. In this particular case, the evidence says the opposite.
Propranolol, metoprolol, bisoprolol: does the choice matter?
Beta blockers are not all the same, and the differences aren’t just branding. The main split is between the nonselective ones, like propranolol, which block beta 1 receptors on the heart and beta 2 receptors elsewhere in the body, and the cardioselective ones, like metoprolol and bisoprolol, which mostly stick to the beta 1 receptors on the heart. On the surface, you’d think the cardioselective drugs would be the obvious pick for POTS, since the problem is a racing heart and those drugs target the heart more cleanly.
The evidence, such as it is, points the other way. The guideline position is that far less is known about the benefit of the cardioselective beta blockers in POTS, and nonselective blockade with propranolol is preferred.[4] Almost all of the good trial data we have, the low dose benefit, the exercise capacity findings, the dose paradox, comes from propranolol specifically.[1][2] When the exercise study did test a high dose of metoprolol head to head against high dose propranolol, neither improved exercise capacity, so that particular comparison doesn’t rescue the cardioselective side either.[2] The honest summary is that propranolol is the one that’s actually been studied, and the alternatives are used more on habit and availability than on evidence.
That said, individual people respond very differently, and this is where the research and the lived reality diverge a bit. Spend any time in POTS communities and you’ll find someone who got nothing from propranolol and a genuine turnaround from bisoprolol, sitting right next to someone who says the exact opposite. That variability is real, and it’s not a reason to dismiss anyone’s experience. What the evidence gives us is a sensible default and a rank order of confidence, not a guarantee for any one body. If propranolol suits you, the research is firmly on your side. If it doesn’t, a cardioselective option is a reasonable thing to discuss, just with the honest caveat that you’re now in territory the trials haven’t mapped as well.
Who beta blockers actually suit, and who they don’t
POTS is an umbrella, and underneath it sit people whose bodies are doing quite different things. This matters more for beta blockers than for almost any other treatment, because the same drug that rescues one subtype can sink another. The group that tends to do best is the one often labelled hyperadrenergic POTS, where the sympathetic nervous system is running genuinely hot. In these people, the level of noradrenaline measured after standing is high, and researchers have used a threshold of around 600 pg/mL of standing noradrenaline to define the group in trials.[6] If your POTS is being driven by an over active adrenaline system, it makes intuitive sense that a drug which blunts that system has something real to push against. You can read more about that particular pattern in our piece on hyperadrenergic POTS and what actually helps.
The group that tends to struggle is the one whose main problem is low blood volume or blood pooling rather than a hyperactive nervous system. If your circulation is already running on the low side, a drug whose job is to reduce the heart’s output can tip you from coping to not coping. This is exactly the scenario behind the stories you’ll hear of someone taking propranolol and ending up in A and E after their blood pressure dropped through the floor. The guideline reflects this, steering towards a different class of medication, the rate limiter ivabradine, when someone has a tendency to low blood pressure, precisely because ivabradine slows the heart without the same blood pressure penalty.[4] If you want the detail on that alternative, we’ve covered it in our review of ivabradine for POTS.
One straightforward safety point gets forgotten in the POTS conversation. Nonselective beta blockers like propranolol block beta 2 receptors in the airways as well as the beta 1 receptors on the heart, and blocking those airway receptors can tighten the airways. For most people that’s a non issue, but if you have asthma it can be a genuine problem, and the guideline specifically names comorbid asthma as a reason to reach for ivabradine instead.[4] This is the kind of thing that should come up in the conversation before the prescription, not after. If it didn’t, it’s worth raising yourself.
The honest read on all of this is that beta blockers are a targeted tool, not a blanket fix. They suit the adrenaline driven end of POTS, they’re risky at the low volume, low pressure end, and they need care around asthma. Working out which end of that spectrum you sit on is far more useful than arguing about beta blockers in the abstract, and it’s a conversation your cardiologist or POTS specialist can help with, sometimes using a standing catecholamine measurement to see how hard your sympathetic system is actually working.
Where beta blockers sit in the bigger picture
This is the part that rarely makes it into a five minute appointment, and it’s the elephant in the room for the whole conversation. At their best, beta blockers are one tool inside a much bigger stack, and they are not the tool doing most of the work.
Every serious guideline on POTS says the same thing: the foundation of treatment is not a tablet at all, it’s the boring, repetitive, unglamorous stuff.[4] Getting your fluid and salt up to expand blood volume, using compression to fight the pooling in your legs and abdomen, and rebuilding your tolerance to being upright in a graded, sensible way. We’ve written about the volume side in detail in our guides to POTS and salt and compression garments for POTS and hypermobility, because those levers are genuinely powerful and cost almost nothing.
The exercise piece deserves special mention, because there’s a study that puts beta blockers in their place rather bluntly. Qi Fu and colleagues compared a structured exercise training programme against propranolol in people with POTS.[3] Both lowered the standing heart rate, so on that one number they looked similar. On the things that actually matter to a life, they were not similar at all. Exercise training improved quality of life clearly and significantly, lifting people’s physical functioning scores from the low 30s into the 50s, while propranolol left those same scores essentially unchanged. Training also preserved the amount of blood the heart pushed out with each beat, whereas the drug did not. The authors concluded, in plain terms, that exercise training is superior to propranolol at restoring upright circulation.
That programme was no small thing, to be fair. It started people off exercising in a horizontal or semi reclined position, on a recumbent bike or a rowing machine, exactly so they weren’t fighting gravity while their bodies were still deconditioned, and it built up slowly over three months towards upright activity, alongside a proper push on salt and fluids.[3] That reclined starting point is the detail most people get wrong when they try to exercise with POTS, and it’s the whole thrust of our article on the first step everyone misses with POTS and exercise. The takeaway is not that medication is pointless. It’s that if you’re going to put effort anywhere, the graded exercise and volume work is where the biggest return lives, and the beta blocker is there to make that work more tolerable, not to replace it.
There’s a subtlety here that’s easy to miss, though. The same guideline that recommends low dose propranolol also warns that its side effects can worsen exercise tolerance and fatigue, and it flags that this is particularly awkward when someone is trying to carry out an exercise programme.[4] So a beta blocker can, in the wrong dose, actively undercut the very treatment that helps most. That’s not a reason to avoid it. It’s a reason to keep the dose low, to notice whether the drug is helping you move more or move less, and to treat that as real information rather than a personal failing. There’s a genuine difference between a medication that dulls a number on a monitor and a medication that improves your function and your day. If your resting numbers look calmer but you’re spending more of your life on the sofa, that’s a question worth sitting with.
What the wider evidence actually shows
So what does the whole body of evidence say when you step back from any single trial? Well, if we’re being honest, it’s thinner than you’d hope for a drug this commonly prescribed. A 2025 systematic review pulled together every randomised trial of POTS treatments it could find, and came up with 21 trials covering around 750 people in total, spread across more than two decades.[5] That is not a lot of people for a condition this widespread, and most of those individual trials were small and short. The review’s own conclusion was blunt: the evidence base is not yet strong enough to firmly settle whether the mainstay drugs, beta blockers included, should be first line treatments, and large properly powered trials are still needed.[5] Moderate confidence is about as good as it gets in this field, so take that as the state of play rather than a criticism of any one study.
The most direct recent comparison worth knowing about is a 2026 crossover trial that pitted propranolol against ivabradine and a placebo in the same group of people with POTS.[7] As reported, both active drugs brought the standing heart rate down to a similar degree, with no clear winner between them on that measure, though ivabradine appeared to give slightly more support to blood pressure. It’s a small trial and its full results aren’t openly available yet, so treat that as a provisional signpost rather than the final word, but it fits neatly with everything else: beta blockers and their rate limiting cousin are broadly in the same ballpark for slowing the heart, and the choice between them comes down to your subtype, your blood pressure and how you personally tolerate them.[4][7]
Put all of that together and the picture is reasonably clear, even if the evidence underneath it is patchy. Low dose propranolol has the best supporting data of any beta blocker in POTS, it earns a genuine recommendation in the guidelines for the right person, and it can meaningfully help with the racing heart and with exercise tolerance.[1][2][4] At the same time, it’s not a cure, it doesn’t outperform the fundamentals of volume and graded movement, and pushed too hard it turns on you.[3][4] That’s a useful if slightly deflating truth, and it’s a much better place to start a conversation with your prescriber than either blind faith or blanket rejection.
The bigger nervous system picture
It’s worth zooming out for a moment, because POTS rarely turns up on its own. It travels with hypermobility and Ehlers Danlos syndrome, with mast cell issues, and very often with a nervous system that’s been stuck in a high arousal, high alert state for a long time. That last part matters for beta blockers specifically, because a chunk of the racing heart, the shakiness and the sense of being permanently wired can come from an over active stress response rather than the circulation problem alone. We treat that whole loop as part of the picture, not a separate issue, and it’s why some people notice a beta blocker takes the physical edge off their anxiety as well as their heart rate. If that rings true, our article on why hypermobile bodies are wired for anxiety digs into the mechanism, and our overview of the POTS, EDS and mast cell trifecta covers how these systems feed one another.
None of that changes the core message, but it does explain why two people with the same heart rate numbers can have such different experiences of the same drug. A beta blocker calms one specific channel of an over active system. Whether that helps you a lot, a little, or not at all depends on how much of your trouble is running through that particular channel. For the fuller view of how POTS is understood and managed now, including where these medications fit, our complete guide to POTS and dysautonomia is the place to start, and it’s worth reading our breakdown of what the 2026 POTS guidelines changed alongside it.
Frequently asked questions
Are beta blockers a cure for POTS?
No, and I’d be wary of anyone who framed them that way. A beta blocker can take the top off the racing heart and, at a sensible low dose, make activity more tolerable, but it doesn’t fix the underlying circulation problem.[1][4] The treatments that shift POTS most reliably are the unglamorous ones, expanding blood volume with salt and fluid, using compression, and rebuilding tolerance to being upright through graded exercise, and at least one trial found structured exercise training clearly outperformed propranolol on quality of life.[3][4] Think of a beta blocker as something that can make the real work more doable, not a replacement for it.
Why do beta blockers make me so tired?
Fatigue and reduced exercise tolerance are among the most common side effects, and the guidelines name them directly.[4] Often it comes down to dose. A dose that’s higher than you need slows the heart so much that it cuts into the output your body genuinely relies on to reach your brain and muscles, and the result is feeling flat and wiped out. This is exactly the pattern the research found, where a higher dose lowered heart rate more but left people feeling worse than a lower dose did.[1][2] If a beta blocker is flattening you, that’s real information worth taking back to your prescriber, and a lower dose is often the answer rather than abandoning the drug altogether.
Which beta blocker is best for POTS?
On the evidence, low dose propranolol is the default choice, because it’s the one with the most supporting trial data and the guidelines specifically prefer nonselective blockade over the cardioselective options like metoprolol and bisoprolol.[1][2][4] That said, people respond very differently in practice, and plenty of people who got nothing from one beta blocker do well on another, so a cardioselective option is a reasonable thing to discuss if propranolol doesn’t suit you. Just go in knowing that the alternatives are less well studied, so you’re relying more on trial and error and less on published evidence.
Can I take beta blockers if my blood pressure is low?
This is where beta blockers can cause trouble, and it’s a real conversation to have with your doctor rather than something to sort out alone. Because a beta blocker reduces the heart’s output, it can push an already low blood pressure lower, which is why some people feel worse or even faint on them.[4] For people with a tendency to low blood pressure, the guideline leans towards ivabradine instead, since it slows the heart without the same blood pressure penalty.[4][7] If your POTS runs alongside low blood pressure or a lot of blood pooling, make sure whoever prescribes for you knows that, because it genuinely changes which medication is sensible.
Do I have to take beta blockers forever?
Not necessarily. Plenty of people use a beta blocker as a bridge, something that makes the early stages of rebuilding tolerance more manageable, and find their reliance on it drops as their volume, fitness and overall stability improve. The exercise research supports that direction of travel, with training improving upright circulation and quality of life over a few months.[3] Coming off any heart medication should always be done gradually and with your prescriber, never abruptly on your own, but the goal for many people is to need less over time, not to be tied to the tablet indefinitely.
The honest bottom line
If you take one thing from this, let it be the dose lesson. A low dose of propranolol has real, guideline backed evidence behind it for the right person with POTS, and it can genuinely help both the racing heart and your capacity to move, but a bigger dose is not a better one, and pushing it too hard is the fastest way to end up flatter and more exhausted.[1][2][4] Beyond that, beta blockers are one tool in a stack, and they’re not the tool doing the heavy lifting. The volume work, the compression, and above all the patient, graded rebuilding of your tolerance to being upright are what shift the condition most, and the medication is there to make that work more bearable.[3][4]
If you’re already on a beta blocker, this isn’t me telling you to stop. It’s a reason to have an honest conversation with your prescriber about whether it’s actually helping you function, whether the dose is right rather than simply high, and whether your particular flavour of POTS is one this drug suits. And if you’ve been let down by one in the past, it’s worth knowing that a bad experience often says more about the dose or the subtype than about the whole class of medication. You deserve a treatment plan built around how your body actually works, not a tablet handed over without a map. That’s a conversation worth having, and now you’ve got the evidence to have it properly.
– Adam –
References
1. Raj SR, Black BK, Biaggioni I, et al. Propranolol Decreases Tachycardia and Improves Symptoms in the Postural Tachycardia Syndrome. Circulation 2009;120(9):725-734. doi: 10.1161/CIRCULATIONAHA.108.846501
2. Arnold AC, Okamoto LE, Diedrich A, et al. Low-dose propranolol and exercise capacity in postural tachycardia syndrome: a randomized study. Neurology 2013;80(21):1927-1933. doi: 10.1212/WNL.0b013e318293e310
3. Fu Q, VanGundy TB, Shibata S, et al. Exercise Training Versus Propranolol in the Treatment of the Postural Orthostatic Tachycardia Syndrome. Hypertension 2011;58(2):167-175. doi: 10.1161/HYPERTENSIONAHA.111.172262
4. Raj SR, Guzman JC, Harvey P, et al. Canadian Cardiovascular Society Position Statement on Postural Orthostatic Tachycardia Syndrome (POTS) and Related Disorders of Chronic Orthostatic Intolerance. Canadian Journal of Cardiology 2020;36(3):357-372. doi: 10.1016/j.cjca.2019.12.024
5. Kwok CS, Lee S, Hall M, et al. The evidence for treatments for postural orthostatic tachycardia syndrome: a systematic review of randomized trials. Trends in Cardiovascular Medicine 2025;35(8):517-527. doi: 10.1016/j.tcm.2025.07.001
6. Taub PR, Zadourian A, Lo HC, et al. Randomized Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome. Journal of the American College of Cardiology 2021;77(7):861-871. doi: 10.1016/j.jacc.2020.12.029
7. Uppal J, Deol P, Giri P, et al. A Randomized Crossover Trial of Ivabradine, Propranolol, and Placebo in Postural Orthostatic Tachycardia Syndrome. JACC: Advances 2026;5(6):102795. doi: 10.1016/j.jacadv.2026.102795
